» Articles » PMID: 9619143

Increased Glutamatergic Neurotransmission and Oxidative Stress After Alcohol Withdrawal

Overview
Journal Am J Psychiatry
Specialty Psychiatry
Date 1998 Jun 10
PMID 9619143
Citations 54
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Neurophysiological and pathological effects of ethanol may be mediated, to an important extent, via the glutamatergic system. Animal studies indicate the acute effects of ethanol disrupt glutamatergic neurotransmission by inhibiting the response of the N-methyl-D-aspartate (NMDA) receptor. Persistent attenuation of glutamatergic neurotransmission by chronic ethanol exposure results in the compensatory up-regulation of NMDA receptors. Whether glutamatergic neurotransmission and oxidative stress are enhanced during ethanol withdrawal in humans is unknown.

Method: CSF was obtained from 18 matched comparison subjects and from 18 patients with alcohol dependence 1 week and 1 month after cessation of ethanol ingestion. CSF samples were analyzed for excitatory neurotransmitters, gamma-aminobutyric acid (GABA), and markers for oxidative stress.

Results: The alcohol-dependent patients' CSF levels of aspartate, glycine, and N-acetylaspartylglutamate were all higher than those of the comparison subjects, and their concentration of GABA was lower. In addition, there were significant correlations between excitatory neurotransmitters and oxidative stress markers, which suggest that the two mechanisms may play an interactive role in neurotoxicity mediated by ethanol withdrawal.

Conclusions: The data suggest that augmentation of excitatory neurotransmission may lead to enhanced oxidative stress, which, in concert with reduced inhibitory neurotransmission, may contribute to the symptoms of ethanol withdrawal and associated neurotoxicity in humans. Whether these abnormalities represent a trait- or state-dependent marker of ethanol dependence remains to be resolved.

Citing Articles

Aberrant glutamatergic systems underlying impulsive behaviors: Insights from clinical and preclinical research.

Yates J Prog Neuropsychopharmacol Biol Psychiatry. 2024; 135:111107.

PMID: 39098647 PMC: 11409449. DOI: 10.1016/j.pnpbp.2024.111107.


Ceftriaxone as a Novel Therapeutic Agent for Hyperglutamatergic States: Bridging the Gap Between Preclinical Results and Clinical Translation.

Abulseoud O, Alasmari F, Hussein A, Sari Y Front Neurosci. 2022; 16:841036.

PMID: 35864981 PMC: 9294323. DOI: 10.3389/fnins.2022.841036.


Multimodal neuroimaging of metabotropic glutamate 5 receptors and functional connectivity in alcohol use disorder.

Smart K, Worhunsky P, Scheinost D, Angarita G, Esterlis I, Carson R Alcohol Clin Exp Res. 2022; 46(5):770-782.

PMID: 35342968 PMC: 9117461. DOI: 10.1111/acer.14816.


Astroglia in the Vulnerability and Maintenance of Alcohol Use Disorders.

Miguel-Hidalgo J Adv Neurobiol. 2021; 26:255-279.

PMID: 34888838 DOI: 10.1007/978-3-030-77375-5_11.


Persistence of cerebellar ataxia during chronic ethanol exposure is associated with epigenetic up-regulation of Fmr1 gene expression in rat cerebellum.

Dulman R, Auta J, Wandling G, Patwell R, Zhang H, Pandey S Alcohol Clin Exp Res. 2021; 45(10):2006-2016.

PMID: 34453331 PMC: 8602769. DOI: 10.1111/acer.14691.